Takeda to release Prevacid follow-up in 2008
Hasegawa said the drug, which has not been disclosed in the company's pipeline list, is a 50-50 joint venture with Abbott Laboratories.
Hasegawa said further details about the product would be unveiled soon.
Prevacid is Takeda's top-seller with global sales topping $3.4 billion in 2004/2005.
The drug is marketed in the U.S. by TAP Pharmaceuticals, also joint venture between Takeda and Abbott.